These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 30666796)

  • 1. Targeted inhibition of histone deacetylase 6 in inflammatory diseases.
    Ran J; Zhou J
    Thorac Cancer; 2019 Mar; 10(3):405-412. PubMed ID: 30666796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
    Cosenza M; Pozzi S
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
    Brindisi M; Saraswati AP; Brogi S; Gemma S; Butini S; Campiani G
    J Med Chem; 2020 Jan; 63(1):23-39. PubMed ID: 31415174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
    Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
    Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
    Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
    Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HDAC6 activity in kidney diseases: a new perspective.
    Ke B; Chen Y; Tu W; Ye T; Fang X; Yang L
    Mol Med; 2018 Jun; 24(1):33. PubMed ID: 30134806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
    Oh BR; Suh DH; Bae D; Ha N; Choi YI; Yoo HJ; Park JK; Lee EY; Lee EB; Song YW
    Arthritis Res Ther; 2017 Jul; 19(1):154. PubMed ID: 28673326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure, Functions and Selective Inhibitors of HDAC6.
    Liang T; Fang H
    Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HDAC6, a very specific deacetylase with a potential therapeutic role].
    Osseni A; Schaeffer L
    Med Sci (Paris); 2022 Dec; 38 Hors série n° 1():6-12. PubMed ID: 36649628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of histone deacetylase reduces lipopolysaccharide-induced-inflammation in primary mammary epithelial cells by regulating ROS-NF-кB signaling pathways.
    Wang J; Zhao L; Wei Z; Zhang X; Wang Y; Li F; Fu Y; Liu B
    Int Immunopharmacol; 2018 Mar; 56():230-234. PubMed ID: 29414656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Development of Novel HDAC6 Isoform-selective Inhibitors.
    Zhao Y; Liang T; Hou X; Fang H
    Curr Med Chem; 2021; 28(21):4133-4151. PubMed ID: 33176627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
    Adewole KE; Ishola AA
    Curr Drug Discov Technol; 2021; 18(3):423-436. PubMed ID: 32357815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs.
    Cantley MD; Haynes DR
    Inflammopharmacology; 2013 Aug; 21(4):301-7. PubMed ID: 23341163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
    Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
    J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel class of anthraquinone-based HDAC6 inhibitors.
    Song Y; Lim J; Seo YH
    Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.